Pankaj Agarwal is a GSK Senior Fellow. Since 1996, he has been on a quest at GSK to discover drugs, targets and indications using algorithms and machine learning. He has published innovative methods for gene set enrichment, literature analysis, network analysis, target identification, connectivity map, and drug repositioning. He has done strategic work on evaluating innovation in industry pipelines and identifying disease areas for investment. He has led GSK-wide efforts on systematic drug repurposing. Pankaj obtained a B. Tech. in Computer Science & Engineering from IIT, Delhi, Ph.D. in Computer Science from the Courant Institute of Mathematical Sciences, New York University. He was one of the founding members and directors of the International Society for Computational Biology (ISCB). He serves on the Translational Medicine Advisory Committee for PhRMA.
, M.D., MPH
Assistant Professor and Chief Innovation Officer, Medicine
ICHAN SCHOOL OF MEDICINE, MOUNT SINAI, NY
Ashish Atreja – Assistant Professor and Chief Innovation Officer, Medicine
ICHAN SCHOOL OF MEDICINE, MOUNT SINAI, NY
Dr. Atreja is a healthcare executive with board certification in internal medicine, gastroenterology and clinical informatics. As Chief Innovation Officer, Medicine, he leads the Sinai AppLab (http://www.applab.nyc) that is one of the first collaborative hub within academic medical center to build and test disruptive mhealth technologies. As an intrapreneur, Dr. Atreja has won innovation awards at Cleveland Clinic and Mount Sinai, successfully licensed
technologies from academic centers and advises startups, accelerators and Fortune 500 companies in digital medicine. He was first gastroenterologist to get board certified in informatics and one of the first to develop virtual pager and messaging application. Dr. Atreja serves as Scientific Founder for Mount Sinai Spinoff, Rx.Health that brings first enterprise- wide app curation, prescription and engagement platform to risk sharing hospitals and payers in an affordable and scalable manner. Recently, Dr. Atreja established non-profit Network of Digital Medicine (NODE.Health) to connect innovation centers worldwide and share best practices for digital medicine innovation and implementation between industry, payers and health systems. Dr.Atreja is a member of many professional organizations, has published 70 academic papers, presented more than 200 abstracts and has been a keynote speaker globally on topics related to digital medicine evidence and health system transformation. Dr. Atreja was nominated among the Top 40 HealthCare Transformers in 2017.
Executive Director, Real-World Data Analytics
John Cai – Executive Director, Real-World Data Analytics
Dr. Zhaohui (John) Cai is Executive Director, Real-world Data Analytics and Innovation, in the Merck Center for Observational and Real-World Evidence. He is leading a team of data scientists and outcomes researchers to generate scientific evidence and insights through advanced analytics and predictive modelling. John has 20 years of experience in biomedical and clinical research across academic, biotech, and pharmaceutical settings. John received his medical training from China Medical University and his Medical Informatics training from the Children’s Hospital Informatics Program in Harvard Medical School. Pursuing a passion for both medicine and computing, John has co-authored peer-reviewed publications in the areas of medical informatics, machine learning/data mining, clinical trials, and cancer genomics. He also serves in the American Medical Informatics Association (AMIA) Industry Advisory Council.
Irene is the Director of Drug Discovery at Verge Genomics in San Francisco, CA. She has spent her career in early drug discovery in neuroscience and oncology having led multiple programs, one of which was of a novel opioid analgesic with demonstrated efficacy in Phase 3 clinical trials. At Verge Genomics, she works with biologists and computational scientists to test artificial intelligence enabled machine learning predictions at the bench to identify novel therapeutics in neurodegenerative diseases.
Associate Director, Translational Medicine and Emerging Innovations
Leslie Cousens – Associate Director, Translational Medicine and Emerging Innovations
Leslie earned her Ph.D. in biology and medicine, with a focus on immunology, from Brown University in 1999. Her academic research experience in cellular and molecular immunology includes basic science in small animal models through translational science in cellular immunotherapy. Prior to AstraZeneca, she was leading the research and development efforts for a small biotech company in Providence, Rhode Island. Leslie joined AstraZeneca’s Emerging Innovations Unit in January 2015, where they take an entrepreneurial approach to deliver new medicines through drug repositioning by leveraging external science via the pioneering “open innovation” platform, by incubating novel technologies and by project partnering.
Savan Devani is the Founder and CEO of BioTrillion, a health technology company developing BioEngine4D to digitally detect developing diseases.
Previously, Savan spent the majority of his 15 year career in the Life Sciences industry working as a healthcare investment banker with hundreds of innovators. From Analyst through Managing Director, Savan led 40 deals, totaling $35 billion, across the drug, diagnostic, and device spectrum. Savan began his career as a little bioengineer in a big lab at Life Technologies.
Savan graduated with a B.S.E. in Bioengineering from the University of California at Berkeley and a M.S.E. in Bioengineering from the University of Pennsylvania.
A deeply personal experience later in life made Savan truly realize how much in healthcare needed to change – his mother was suddenly diagnosed with stage IVb cancer – which compelled asking “where were all the signs” and “isn’t there a better way,” which led to BioTrillion.
Senior Group Director, Global Regulatory Pharmacovigilance Innovation Policy
Bruce Donzati – Senior Group Director, Global Regulatory Pharmacovigilance Innovation Policy
Bruce has a PhD in pharmacology/neuroscience with almost 30 years of experience in the pharma/biotech industry. After serving in the US Army, he entered academics where he performed research on mechanisms of neuronal degeneration and neurotoxicology and lectured in neuropharmacology. He continued his pre-clinical research in industry before moving into clinical development and eventually Medical Affairs. Bruce has held various positions in industry, including Head of Drug Safety at Genentech and now Senior Group Director of Pharmacovigilance Innovation Policy in Regulatory Affairs. In this role, Bruce works with key stakeholders to focus on new methodologies such as AI in pharmacovigilance.
Associate Director Materials and Innovation
Ronald Dorenbos – Associate Director Materials and Innovation
As Associate Director of Materials & Innovation and as a member of Takeda’s Digital Strategy team for Neuroscience Ronald helps Takeda with its technology and innovation strategy, identifying technologies that can benefit Takeda’s core areas Oncology, Neuroscience and Gastroenterology. Earlier, at the Life Science division of PA Consulting, Ronald led projects for some of the world’s top 10 pharmaceutical companies that included projects around strategy, commercialization, and digital health and at his company BioFrontline he provided management, strategy and commercial advice to life sciences companies around the world. After obtaining MAs in Biotechnology and Molecular Biology and a Ph.D. in Pharmaceutical Biology he spent six years at Harvard studying Parkinson’s, Schizophrenia and the genetics of aggressive behavior before making the transition to industry. Ronald is a keen follower of applications of AI and deep learning in pharma and healthcare and is the founder of the LinkedIn group 'AI – Artificial Intelligence.'
Andrew’s executive and entrepreneurial experience spans 20 years in B2C and B2B, for startups and Fortune 500 companies. Andrew founded and sold three technology companies and today is the CEO and Founder of ClosedLoop.ai – an AI based predictive analytics platform focused on maximizing the value of raw, messy, real world healthcare data in predicting health outcomes.
Prior to founding ClosedLoop, Andrew co-founded the mobile software company Boxer. Boxer’s flagship email product was downloaded by millions of users and received industry praise for its exceptional user interface, including a 2015 Webby Nomination as one of the top 5 productivity applications in the world. Boxer was purchased by VMWare in 2015.
In 2007 Andrew co-founded the cyber security firm Ciphent. Ciphent grew to nearly 100 employees with 1,000 customers before being acquired by Optiv. Ciphent was recognized by Inc. Magazine as the 2010 #16th Fastest Growing Private Company in the United States.
Director, R&D Information
Jane Fang – Director, R&D Information
Head of U.S. Health Informatics and Analytics (Sr. Assoc. Director, Biostatistics and Data Sciences)
Victoria Gamerman – Head of U.S. Health Informatics and Analytics (Sr. Assoc. Director, Biostatistics and Data Sciences)
Senior Vice President, Clinical Innovations
SAAMA TECHNOLOGIES, INC.
Amit Gulwaldi – Senior Vice President, Clinical Innovations
SAAMA TECHNOLOGIES, INC.
Amit executes Saama’s clinical analytics innovation roadmap by identifying and integrating emerging concepts across the clinical research value chain, fostering and strengthening clinical ecosystem relationships, and communicating Saama’s strategy to key stakeholders.
Charged with helping Saama positively impact the clinical research value chain by improving the pharmaceutical industry’s existing clinical analytics ecosystem, Amit collaborates closely with Saama’s Board of Advisors, product management and marketing teams, customers and partners, including CROs, healthcare-technology startups and data providers. Amit is leading the development of a clinical innovation ROI model to differentiate Saama’s competitive value to customers.
Amit leads Saama’s engagement with emerging clinical process and analytic technology companies, as well as the venture capital community, sharing Saama’s macro views on clinical analytics and learning about new and relevant companies that are disrupting industry norms. Amit translates this insight into recommendations for Saama’s leadership to inform investment and partnership decisions. Amit works closely with internal business and technology groups to understand and help shape their strategies and goals related to application development, artificial intelligence and machine learning, clinical technology, enhanced user experiences, collaboration, mobile, wearables, and big data.
Amit organizes and leads executive briefings and follow-up with customers, vendors, and partners to identify areas and opportunities to innovate, optimize the end-user experience, and increase Saama’s business-enabling capabilities through partnerships with innovative data providers and CROs.
Evon Holladay is a seasoned professional in architecting enterprise intelligence solutions and running analytics operations. She has built scalable, high-value solutions for healthcare, telecommunications, retail, and manufacturing. She is passionate about working with a broad range of stakeholders to develop a strategy and then operationalize the strategy into solutions that provide measurable value.
As the former Vice President Enterprise Intelligence for Catholic Health Initiatives (CHI), she led CHI’s Population Health Analytics and Data strategy. This included the formation of an industry-leading information management governance structure for CHI’s analytics portfolio, enterprise data warehouse, data governance and enterprise information architecture.
Currently, she is using her research skills to help provide new insight into the health-healthcare-health insurance conundrum. She is collaborating with a broad range of viewpoints — in the US and internationally — ranging from health economists, healthcare providers, health insurance, and alternative medicine. Her research is focused on the impact of healthcare spending on personal income and the changes in the health of the US population.
She also is an analytics advisory board member for DU’s Business Information and Analytics department. She regularly presents her work nationally and internationally. At DU she guest-lectures and works with her business peers to provide timely capstone project opportunities.
Alex (Wen-Yaw) Hsieh – Director — Clinical Development Quality
Alex Hsieh is a Director of Clinical Development Quality Analytics in Quality Performance and Risk Management in Pfizer Clinical Development Quality. Alex joined Pfizer in 1999. During the past twenty years, Alex held progressively responsible roles, moving from positions of Statistician to Operational Excellence specialist/Master Black Belt, Project Manager, Risk Management facilitator, and most recently, to the director role in Quality Performance and Risk Management responsible for using quality analytics, including utilization of multivariate statistics and machine learning techniques, to drive quality excellence of our clinical trials.
Alex has a breadth of experience in Pharmaceutical Sciences and Clinical Development, particularly with Good Laboratory Practice (GLP), Good Manufacturing Practice (GMP), and Good Clinical Practice (GCP). He supported several new product development as well as other developing compounds. Alex holds a B.S. in Physics from Fu Jen Catholic University, a Master’s Degree in Statistics from Columbia University, and another Master’s Degree in Pharmaceutical Engineering from the University of Michigan. He also is an American Statistical Association (ASA) – Accredited Professional Statistician (PStat®), American Society for Quality (ASQ) – Certified Master Black Belt (CMBB), Certified Six Sigma Black Belt (CSSBB), Certified Quality Engineer (CQE), and PMI’s Project Management Professional (PMP) and Risk Management Professional (RMP).
Senior Manager A.I./Machine Learning Development
Kevin Hua – Senior Manager A.I./Machine Learning Development
Dr. (Kevin) Hua has 20 years of experience working in design and development of AI/Machine Learning applications in healthcare, insurance, banking, retails and manufacturing industries. He is currently a senior manager with the Digital Health Intelligence Group of Bayer, responsible for developing AI/ML applications. Prior to Bayer, he was a machine learning specialist at Deloitte Consulting and a research manager of AI at Center for Advanced Research of PwC. His work in analytics has won the Analytics Leadership Award from IU Kelley School of Business in 2014 and INFORMS Data Mining contest in 2008.
Theo is a business driven technology executive with expertise ranging from technology transformation, cloud computing, digital business models to databases and data analytics. With prior experiences in application development to infrastructure services, Theo has a unique perspective on the key roles that Machine learning, Artificial Intelligence and IOT play in harnessing data to make sustainable business decisions. He has advised CEOs on making the transition from traditional business models to digital business models. In his current role as the CTO for Kaleida Health, he is responsible for wide-ranging technology initiatives that is influencing healthcare. In his free time you will find Theo enjoying and coaching the beautiful game – Soccer.
, RN, M.S., MBA
Innovation and Digital Health Lead
Gena Koufos RN, MS, MBA is the Innovation & Digital Health Lead at AMAG pharmaceuticals. Gena focuses on surfacing and testing emerging trends, technology, and start-up partnerships to meet unmet patient needs, clinician needs, and business challenges. Gena began her career as a pediatric nurse and later moved into consulting and Digital Health for hospitals and pharma.
Executive Vice President, Industry Liaison and Talent Development
Bio Supply Management Alliance (BSMA)
Director, Outreach and Partnerships, Center for Supply Chain Innovation- TEXAS CHRISTIAN UNIVERSITY
Dave Malenfant – Executive Vice President, Industry Liaison and Talent Development
Bio Supply Management Alliance (BSMA)
M. Dave Malenfant is currently Executive Vice President of Industry Liaison and Talent Development for the BSMA (Biotech Supply Management Alliance). He also serves as Director and oversees the Advisory Board for the Center for Supply Chain Innovation at Texas Christian University. Dave is responsible for driving Industry relations in the Biotech, Biopharma Supply Chain for the BSMA. Prior to this appointment, Dave served on the Advisory Board for the BSMA from its inception. With a passion for talent development and career planning, Dave has helped both the BSMA and the Center for Supply Chain Innovation drive Young Professional career development and mentoring programs for students.
Prior to joining the BSMA and TCU, Dave spent over 30 years in a variety of industry roles. As an entrepreneur, Dave was Co-founder and President of Signature Consultants, Inc., (1973) a business, finance, and economic consulting firm that he ultimately sold in 1993. He created and operated a variety of other businesses that are still profitable in Canada today.
In 1993, Dave joined Alcon Laboratories where he steadily advanced through leadership roles such as Purchasing Manager, Materials Operation Manager, and Global Supply Chain Director before becoming the Vice President of Global Supply Chain in 2005. In this role, Dave provided strategic direction for the company’s Global Supply Chain initiatives and created global centers of excellence for Purchasing, Distribution, Transportation, Customer Service, Sales and Operations Management, Data Management, Graphic Design and Artwork Development, and Product Launches. Dave retired from Alcon in 2014.
Dave is recognized for the creative development of standardized systems and business processes, and for developing enabling technology throughout the entire supply chain. During his career, Dave has implemented over 30 different computer systems — WMS, ERP, Finite Scheduling, Product Launch, and Order Entry, among others. Dave is past Chairman of the Supply Chain Council and past member of the Executive Committee of NASSTRAC.
Given his vast knowledge of the end-to-end, integrated supply chain, Dave is a frequent speaker on Global Supply Chain Trends. He has consistently demonstrated his passion for Supply Chain management, developing talent, and the need to advance Supply Chain theory and innovation throughout a variety of industries.
Brian joined AbbVie in October of 2018 as the head of the newly formed RAIDERS team within Research & Development’s Information Research division, focused on accelerating, scaling, and amplifying the work of AbbVie’s R&D community using AI technologies like machine learning, deep learning, and cognitive computing. Brian came to AbbVie after spending five years in technology consulting across many industries, and over a decade of additional experience before that working in trading and financial markets technology. While his primary focus is AI technologies, his interests are much broader, and he has presented at multiple conferences on topics including optical networking, quantum computing, blockchain, cognitive architecture, and other emerging technology concepts that are all part of digital transformation.
Brian holds a B.S. degree in Computer and Cognitive Science from Alma College and a M.S in Computer Science from the University of Chicago.
Matthew A. Michela has been a healthcare industry executive for 30 years. He joined Life Image as CEO in 2015 with the mission of democratizing data to create an interoperable healthcare ecosystem that creates a connected view of a patient’s journey.
Throughout his career, Matthew has been at the intersection of providers, health
plans, employers, and patients. He has a proven track record helping organizations create novel approaches to value generation, which he has done in several settings.
Executive Director, Center for Health Systems Innovation (CHSI)
OKLAHOMA STATE UNIVERSITY
William Paiva – Executive Director, Center for Health Systems Innovation (CHSI)
OKLAHOMA STATE UNIVERSITY
William D. Paiva, Ph.D., is Executive Director of Oklahoma State University’s Center for Health Systems Innovation (CHSI). The Center is focused on transforming rural and Native America health through the implementation of innovative care delivery and IT solutions. Within CHSI, the Institute for Predictive Medicine is applying advanced analytics to the largest health care database which includes clinical information for over 63 million patients covering 16 years.
Prior to joining Oklahoma State University, Dr. Paiva was a partner, joined Sevin Rosen Funds, a fund with over $2 billion under management, where he brought more than 20 years of venture-capital, biomedical-industry and management-consulting experience to the firm. William specialized in identifying early-stage venture opportunities at the intersection of traditional technology sectors and healthcare. He also used his healthcare expertise and network to assist Sevin Rosen portfolio companies developing applications and services for the healthcare market. Prior to Sevin Rosen, William was a partner at Chisholm Private Capital Partners, where he managed a $100 million fund focused on healthcare and IT. He also worked as a manager at the Oklahoma Life Science Fund, managing $15 million and making investments in diagnostics, services and therapeutics firms.
Before that, William served as a management consultant for the Life Sciences Industry Group at Pittiglio Rabin Todd & McGrath, later acquired by PriceWaterhouseCoopers, where he consulted with the top five pharmaceutical companies on product-development and technology-management projects. William also served as an investment banking associate at JP Morgan in New York, providing strategic and investment banking advisory services to Fortune 100 healthcare companies.
William holds a Ph.D. in molecular biology from the University of Oklahoma; an MBA from Dartmouth College’s Amos Tuck School of Business; a master’s degree in microbiology and immunology from the University of Oklahoma Health Science Center; and a B.S. in microbiology from the University of Oklahoma.
Director, Communities and Initiatives Development, Emerging Technology
IEEE STANDARDS ASSOCIATION
Maria Palombini – Director, Communities and Initiatives Development, Emerging Technology
IEEE STANDARDS ASSOCIATION
Maria is the creator, leader and advocate for the Pharma Blockchain Initiative, which seeks to bring awareness and balanced learning to the pharmaceutical community and its key stakeholders on the viable applications of blockchain within the pharmaceutical framework. The goal of the initiative is the advanced adoption of blockchain in combination with emerging technologies (ie. AI, IoT, etc) where it will lead to enhanced patient safety and care, and optimize and innovate the drug development life cycle.
In 2017, Maria joined IEEE-SA with a directive to build communities and advance initiatives to develop standards for enterprise adoption of emerging technologies. Her work includes building communities of technologists, industry executives, academic researchers and industry stakeholders to educate on the benefits and challenges of viable applications of emerging technologies while building consensus on recommendations for frameworks on technical standards and recommended guidelines for protocol and policies to enhance the outcomes of technology implementation. Her primary areas of focus include the pharma, health, supply chain, energy, and agriculture sectors. In parallel to her work in blockchain standards, she is the project lead for IEEE-SA’s newest initiative, Digital Inclusion through Trust and Agency, a critical program focused on bringing the outstanding 50% of the world’s population online while working with technologists, advocacy groups and policy leaders on developing trusted frameworks that will protect the digital persona, the right to be forgotten, and restoring dignity to digital transactions for ALL members of the global community.
In 2015, Maria left Euromoney Plc, one of the world’s leading information and event producers. She founded DisruptiveRx™, an information company that would produce written and in-person educational programs and bring pragmatic attention to breakthrough innovations that would transform life sciences and healthcare enterprise operations.
Her career started at the prestigious IEEE (Institute for Electronic and Electrical Engineers) and moved onto highly respected media companies including Penton Media, Advanstar Communications, IIR, Reed Business Information and Nielsen Business Media. She successfully led the global branding, marketing, and public relations campaign for the world’s largest mining investment networking platform, Mining Indaba™, in Cape Town, South Africa.
Maria currently holds an MBA from the Rutgers Graduate School of Business and a BA and BS from Rutgers College at Rutgers University, the State University of New Jersey. She is an accomplished leader and public speaker having presented at various industry events. You can follow her on twitter @DisruptiveRx or on LinkedIn.com/in/mpalombini.
, Ph.D., MBA
Director, Global Scientific Affairs Global Health Economics Outcomes Research and Health Policy
Jamie Partridge – Director, Global Scientific Affairs Global Health Economics Outcomes Research and Health Policy
Jamie Partridge, Director, HEOR at Abbott Nutrition leads a team focusing on Health Economics and Outcomes Research, Public Health and Policy. Jamie joined Abbott Nutrition in 2012 and established its HEOR group which focuses on studies in the area of therapeutic nutrition to demonstrate nutrition intervention and quality improvement as a cost-effective way of improving health outcomes. Jamie came to Abbott Nutrition from Abbott Vascular’s HEOR team. Prior to working in industry, Jamie was a researcher in the Center for Health Outcomes, Policy and Evaluation Studies in the College of Public Health at the Ohio State University and served as a faculty member at a variety of universities in the US and Canada. Jamie has a B.A. in Economics from the University of Illinois, an M.B.A in Finance and Operations Management from Indiana University’s Kelley School of Business, and a Ph.D. in Agricultural Economics from the University of Saskatchewan.
Zeenat is currently on the business and partner development team formerly called Google Medical Brain, a machine and artificial intelligence (AI) research institute. She has been instrumental in driving forward the healthcare initiative at Google to provide best in class machine learning tools to a host of healthcare applications, including diagnosing various diseases through computer vision technology, cell painting technology for drug discovery, and using machine learning on unstructured EHR data to name a few core projects. Zeenat also serves on the board of the Northern California Club of the Massachusetts Institute of Technology, and is an advisor to companies in the healthcare space including SwipeSense.
Prior to joining Google, Zeenat spent nearly a decade in the healthcare industry in the corporate development and business development capacity. She was most recently led Corporate Development at Raptor Pharmaceuticals, and was instrumental in the acquisition of Quinsair, the largest acquisition in the company’s history at nearly $400M.
Zeenat has a BS in Biological Sciences from Cornell University, an MBA in from Melbourne Business School and a MS from a joint program (Health,Science,&Technology) at the Massachusetts Institute of Technology and Harvard University.
Denise Pohlhaus is a data scientist in GSK Consumer Health. She has a Ph.D. in Chemistry from UNC-Chapel Hill. She started off as a computational chemist doing pre-clinical drug discovery within GSK Pharma R&D. She used protein simulations methods, physics-based scoring functions, and a variety of cheminformatics techniques to optimize chemistry and increase molecular understanding of pathways relevant to antibiotic drug development, HIV and oncology—resulting in patent applications and publications.
She then moved to GSK Consumer Health to set up and execute statistical capabilities for a team of consumer innovation and sensory scientists. In her current role, she uses traditional (e.g., multivariate regression, DOE) and advanced analytics methods (e.g., Decision Trees, kNN, Random Forest) to understand the desired consumer/sensory experience and to help guide product development scientists on how to formulate products that meet or exceed consumer expectations.
In her spare time, she goes walking and camping with her two young daughters and husband.
Vice President and Chief Information Officer
HACKENSACK UNIVERSITY MEDICAL CENTER
Shafiq Rab – Vice President and Chief Information Officer
HACKENSACK UNIVERSITY MEDICAL CENTER
Head, Artificial Intelligence and Data Science
Prasanna Rao – Head, Artificial Intelligence and Data Science
Prasanna Rao is an AI practitioner and industry thought with over 25 years of experience in Information technology and Analytics, with 10 years in Healthcare and Life Sciences. In his previous role as a Watson Architect at IBM Watson Health, he was instrumental in incubating solutions for transforming clinical trials with innovative solutions like Watson for Clinical Trial Matching. His current role is Head of Artificial Intelligence and Data Sciences for Data Management and Monitoring organization at Pfizer.
Head, AI Center for Excellence
Josh Raysman – Head, AI Center for Excellence
Principal Manager, gRED Pipeline and Portfolio Planning
Michael Sachs – Principal Manager, gRED Pipeline and Portfolio Planning
Malaikannan Sankarasubbu is the VP of AI Research in Saama Technologies. He is currently working on optimizing and accelerating clinical trials using Artificial Intelligence. He specializes in deriving insights with unstructured data like text and images. He previously was Founder and CTO for Datalog.ai creators of MyPolly, a chatbot building platform with its own Natural Language Understanding Engine where he built a community of 1,200 active developers, aka chatbot builders, around MyPolly. Malaikannan was part of the Enterprise Architecture team in Optum and Cognizant Technology Solutions. He understands Healthcare and is passionate about advancing more applications of Deep Learning in Healthcare and Life Sciences. Malaikannan loves building community; he along with few others built a community around Keras and he also created an active forum Indian Deep Learning Initiative which has over 4,500 members. Malaikannan actively shares his knowledge in Meetups and conferences and loves to blog about Artificial Intelligence at malaikannan.io.
, R.Ph., MBA, LSSMB
Senior Director of Product Development and Innovation
Christine Sawicki – Senior Director of Product Development and Innovation
Christine leads innovation for CVS Health’s Specialty division. Her team identifies and introduces solutions that improve patient experience, enhance clinical care, and provide cost-effective solutions to deliver the highest level of clinical care.
Ms. Sawicki has more than 25 years’ experience with CVS Health. She has also led pharmacy design and technology and pharmaceutical water system innovation and was a practicing pharmacist in the health plan, retail, hospital, and long-term care settings. Christine is a three-time CVS Health Breakthrough Award recipient for innovations and business solutions.
Ms. Sawicki received holds a B.A. in Chemistry from Assumption College where she is also adjunct faculty for MBA and Health Advocacy programs, Pharmacy Degree from MCPHSU, MBA from Anna Maria College, Lean Six Sigma Master Black Belt from Villanova University, and Pharmacoeconomic Certification from the University of South Carolina.
Dr. Singhal has experience in leading projects that apply big data, machine learning and artificial intelligence techniques for understanding molecular mechanisms that promote cancer and to deploy the generated knowledge for improvement of cancer care. Dr. Singhal is a lead data scientist at Roche, where he works in personalizing cancer immunotherapy. Previously, Hari was a cancer genomics scientist at Harvard Medical School. He completed his PhD in oncology at University of Chicago and Masters from Johns Hopkins University.
Enterprise Director of Data Analytics, Enterprise Data and Analytics (EDA)
Justin Smith – Enterprise Director of Data Analytics, Enterprise Data and Analytics (EDA)
Justin Smith, Ph.D. leads the development of advanced analytics as Enterprise Director of Data and Analytics for Sanford Health, an organization with over 29,000 employees, 43 hospitals, and 250 clinics across nine states and three countries.
Dr. Smith leads teams, in collaboration with executive leaders, to build machine learning models that enable Sanford to better understand business drivers. Dr. Smith employs a unique skill set of strong analytical skills and thought-leadership as Sanford Health transitions from the world of advanced analytics to artificial intelligence.
Dr. Smith has published numerous articles in peer-reviewed international journals. He holds a Ph.D. in the field of Neuroscience and an M.S. and B.S. in Research Psychology.
Dr. Kelly Stanton is a bioinformatics expert and visiting scientist at Yale University, applying statistics, signal processing and mathematics to analyze DNA sequencing data since 2010. He earned his B.S. in Biomedical Engineering from the University of Texas at Austin and Ph.D. in Bioinformatics at Yale University in 2015. Kelly has published work ranging from bioinformatics applications to new mathematical techniques for general data science use. His post-doctoral work is focused on pioneering new deep learning based algorithms for unsupervised and semi-supervised learning. Currently, Kelly designs predictive analytics for clinical outcomes based on medical IOT data at Potrero Medical. He currently resides in San Francisco, CA.
Jin Yao is a Scientific Investigator in the group of Computational Biology at GlaxoSmithKline. Before joining GSK, he worked as a Postdoctoral Research Associate in the University of Buffalo Medical School where he developed a prognostic biomarker signature to predict drug responders for arthritis patients. He obtained his PhD in Electrical and Computer Engineering from the University of Florida, where his research focused on applying advanced computational methods to solve biological problems in cancer and microbial ecology. His PhD thesis is on developing machine learning algorithms to model breast cancer progression. His research interests are developing and applying machine learning techniques for large-scale genetic and genomic data to understand human disease for personalized medicine.